Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00923052 · ClinicalTrials.gov registry record

The Natural History of Solid Organ Cancer Stem Cells (SOCSC)

A clinical trial, sponsored by National Cancer Institute (NCI).

Terminated
Registry status
190
Enrollment target

NCT00923052: Clinical Trial study, sponsored by National Cancer Institute (NCI).

NCT00923052 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 190 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00923052 was terminated before completion, sponsored by National Cancer Institute (NCI).

TERMINATED
Registry status
190 participants
Enrollment target

Study Summary

Background: * Researchers are trying to learn what causes certain types of cancer to spread to other organs in the body (metastasis). Cancer tumors may produce a very small number of specific cells (cancer stem cells) that cause the tumors to grow in other organs throughout the body. * By examining cancer tumor tissue, normal tissue, blood, bone marrow, and other body fluids, researchers may determine whether these samples contain cancer stem cells. Cancer stem cells may provide information on whether the cancer will come back or spread before other routine x-ray studies or lab tests indicate its presence. Objectives: * To acquire a collection of solid organ cancer stem cells for future study. * To analyze solid organ cancer stem cells from various types of cancer on a genetic level. * To determine if solid organ cancer stem cells are present in the blood or bone marrow. Eligibility: * Patients 16 years of age and older who have solid organ cancer (cancer in the liver, colon, rectum, anus, pancreas, stomach, breast, skin, muscles, fat, connective tissue, uterus, ovary, cervix, vagina, vulva, or inner lining of the abdomen) or a precancerous growth, and who are scheduled to have a biopsy or surgery to remove the cancer as part of their treatment. Design: * This is a prospective trial designed to procure solid organ cancer stem cells before either surgery or biopsy. * All patients registered to this trial will undergo surgery to extirpate their cancer in the NCI * Prior to surgery or biopsy, 8 tablespoons of blood will be drawn. * During the surgery or biopsy, a sample of normal tissue will be removed along with the cancerous or precancerous tissue. If separate consent is given, samples of bone marrow will also be taken. * After discharge, patients will return to the clinic for routine visits every month for the first 3 months following surgery, and then about every 3 months for 2 years, and then every 6 months for 3 years. During the visits, patients will have

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2009-02-09
Est. Completion 2015-05-07

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00923052

The ClinicalTrials.gov registry entry for NCT00923052 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00923052 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00923052 about?

NCT00923052 is a clinical study titled "The Natural History of Solid Organ Cancer Stem Cells (SOCSC)". Background: * Researchers are trying to learn what causes certain types of cancer to spread to other organs in the body (metastasis). Cancer tumors may produce a very small number of specific cells (cancer stem cells) that cause the tumors to grow in other organs throughout the body. * By examining...

What is the current status of trial NCT00923052?

This trial is currently terminated. The enrollment target is 190 participants. The study started on 2009-02-09. Estimated completion is 2015-05-07.

Who is sponsoring clinical trial NCT00923052?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.